Lakewood-Amedex Biotherapeutics Inc. - What You Need to Know

Thinking about looking into Lakewood-Amedex? Before you consider investing, here is a breakdown of what the company does and what you should know.

1. What does this company actually do?

Think of Lakewood-Amedex as a high-tech lab tackling a massive global problem: "superbugs." These are bacteria that have evolved to survive current antibiotics.

The company is developing a new class of drugs called Bisphosphocins®. Their lead product, BC-101, is a topical gel for diabetic foot ulcers and skin infections. They are also testing BC-102, an aerosol treatment for lung infections. Their goal is to create treatments applied directly to the infection site. This avoids the side effects of drugs that circulate through the entire body.

2. How do they make money and are they growing?

The company is currently in the research phase. They are not selling products yet, so they have zero revenue.

In 2025, they spent about $3.8 million on operations, mostly for research and administrative costs. They are burning through cash. By the end of 2025, they had only about $236,400 in the bank. They are a startup trying to turn science into a product. Their survival depends entirely on their ability to raise more money.

3. What is this "Resale" filing about?

You might see news about them "going public," but this filing is a "shelf" registration. It allows early investors to sell about 9.6 million shares on the open market. Crucially, the company receives no money from these sales. These shares represent a large portion of the total stock. If these investors sell, it could push the stock price down.

4. What should I know about their recent financing?

In early 2026, the company sold "Series C Preferred Stock." These shares give special rights to those investors over regular shareholders:

• Conversion: Investors can turn these into regular stock. The price depends on the market, but it won't go below $1.00 per share.
• Dividends: Starting six months after the Nasdaq listing, the company may pay these investors a 9.6% annual dividend. This creates a recurring cash bill for the company.
• Safety Net: If the company is sold or dissolved, these investors get paid back before regular shareholders see a dime.

5. What are the main risks?

Biotech investing is high-risk. Beyond the "all or nothing" nature of drug trials, consider these hurdles:

• The FDA Gauntlet: Getting a drug approved is difficult. The FDA can change requirements or demand expensive new trials at any time.
• Trial Uncertainty: If drugs cause unexpected side effects, the company may have to stop trials. This limits their potential market and future profit.
• Logistics: Their products may require special storage. If hospitals handle them incorrectly, the medicine might stop working.
• Cash Crunch: They have very little cash. If they need more, they will likely issue more shares, which gives you a smaller slice of the company.
• Commercial Hurdles: They have no experience selling medicine. They must build a sales team or find a partner to compete against pharmaceutical giants.

6. Where does it trade?

The stock trades on the Nasdaq under the ticker “LABT.” As of May 1, 2026, the price was $2.66 per share.

A Friendly Reminder: Biotech stocks are bets on science. Because this company has no revenue and very little cash, it is a high-risk investment. Only invest money you are comfortable losing. Before you buy, always look up their latest "10-K" or "10-Q" filings on the SEC website to see if their cash situation has changed.

Disclaimer: I am an AI, not a financial advisor. This guide is for educational purposes and does not constitute financial advice.